Home | Welcome to Contract Pharma   
Last Updated Tuesday, June 2 2015

Print

Search Results for 'biotech'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published April 30, 2012
Program enters lead optimization phase Read More »
Published April 9, 2012
Will be responsible for development and commercialization Read More »
By Gil Roth
Published March 20, 2012
By Gil Roth
Published March 20, 2012
Published February 27, 2012
The industrial use of living organisms (or parts of living organisms) to produce foods, drugs, or other products. The oldest biotechnologies include fermentation and plant and animal hybridization.… Read More »
Published October 25, 2011
Fujifilm Diosynth will use pAVEway protein expression technology Read More »
Published September 8, 2011
Zak takes over financial responsibility as PBS brings SUB to market Read More »
By Gil Roth
Published August 23, 2011
SUB company picks up design, mfg., test capabilities Read More »
By S. Harachand, Contributing Editor
Published June 6, 2011
Generics, vaccines fuel growth Read More »
Published June 6, 2011
Evotec AG has entered into a medicinal chemistry collaboration with Active Biotech AB, following the successful conclusion of a High Throughput Screening campaign to identify small molecule modulators of Active Biotech’s priority biological target involved in immune disorders and cancer. Read More »
Published June 3, 2011
Goodwin Biotechnology, Inc. (GBI) and Alethia Biotherapeutics, Inc. have entered a collaboration for the development of a mammalian cell line-based IgG monoclonal antibody project for the treatment of cancer. Read More »
Published June 2, 2011
Fujifilm Diosynth Biotechnologies is expanding its manufacturing capabilities with the addition of a 1,000L Xcellerex Single-Use Bioreactor at its RTP, NC facility. Read More »
Published May 18, 2011
Goodwin Biotechnology, Inc. (GBI) and Rafagen, Inc. have entered a collaboration agreement for cell line engineering and biological contract manufacturing. Read More »
Published May 12, 2011
Oncolytics Biotech has entered into a commercial supply agreement with SAFC, a division of Sigma-Aldrich Corp., for the commercial manufacture of Oncolytics’ reovirus, Reolysin. Read More »
Published April 1, 2011
The former Merck BioManufacturing Network has been named Fujifilm Diosynth Biotechnologies following the completion of FUJIFILM Corp.’s recent acquisition of the company. Read More »
Published March 14, 2011
PROLOR Biotech, Inc. is relocating its corporate office and R&D facility to a new, larger building located near its current site in the Weizmann Science Park in Nes Ziona, Israel. Read More »
Published February 10, 2011
Evotec AG has signed a definitive agreement to acquire Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company, for $4.1 million in cash. Read More »
Published February 10, 2011
Richman Chemical, Inc. has expanded its service offerings to include biotechnology services ranging from cell line development to media optimization and process characterization. Read More »
Published November 16, 2010
Avecia to expand QMS as oligonucleotides advance Read More »
Published October 18, 2010
Goodwin Biotechnology, Inc. has signed a development and manufacturing agreement with a multinational biopharmaceutical client, under which Goodwin will develop the process to manufacture a therapeutic monoclonal antibody conjugate for diagnostic imaging Read More »
Published October 14, 2010
Dr. Christel Fenge has been named vice president of marketing for Fermentation Technologies at Sartorius Stedim Biotech. Read More »
Biotechnology Trends & Outsourcing
By Lou Schmukler and John Korte
Published October 8, 2010
How has biopharma impacted the outsourcing market? Read More »
Published July 29, 2010
Aptuit, Inc. and Siena Biotech entered into a strategic partnership under which Siena Biotech will take a minority stake in Aptuit’s operations in Verona, Italy and Aptuit will serve as Siena’s provider of choice for its development pipeline. Read More »
Published July 8, 2010
OctoPlus N.V. has signed an agreement with an undisclosed U.S. biotechnology company for the use of OctoPlus' controlled release technology. Read More »
Published July 6, 2010
Pharmatech Oncology to help run Phase II Ranpirnase trial Read More »
Published April 29, 2010
Goodwin Biotechnology Inc., a full service contract biomanufacturing company, and Hyprocell LLC, a provider of clinical cell line development services, have entered into a collaboration agreement to create a business model enabling customers to access the Read More »
Published February 8, 2010
Teva Pharmaceutical Industries, Ltd. and Active Biotech have amended their marketing and distribution agreement for oral laquinimod, an investigational drug for relapsing-remitting multiple sclerosis (RRMS). Read More »
Published October 30, 2009
Eli Lilly and Co. has opened its new Biotechnology Center in San Diego, as part of its strategy to develop more biopharmaceuticals. Read More »
Published September 29, 2009
Laureate Pharma has entered into a development and manufacturing agreement with ZZ Biotech, LLC, under which Laureate will produce Activated Protein C variant under cGMP conditions. Read More »
Published June 25, 2009
Teva, Active to begin second Phase III trial of Avonex competitor. Read More »
Published June 25, 2009
Teva, Active to begin second Phase III trial of Avonex competitor. Read More »
Published June 12, 2009
Dr. Yujing Yang has assumed the position of director of Purification Technologies, North America, at Sartorius Stedim Biotech. Read More »
Published June 5, 2009
Ortho Biotech Oncology R&D, a unit of Centocor R&D, Inc., has entered into a five-year Cooperative R&D Agreement (CRADA) with the National Cancer Institute (NCI) to research and develop new cell therapy technologies as potential cancer treatments. Read More »
Published May 26, 2009
Johnson & Johnson and Cougar Biotechnology, Inc. entered a definitive agreement under which J&J will acquire Cougar Biotechnology for approximately $1.0 billion in cash. Read More »
Published May 12, 2009
Sartorius Stedim Biotech expanded its technology portfolio with the addition of two prototypes of single-use bioreactors that operate based on novel mixing technologies. Read More »
By Gil Roth
Published April 1, 2009
With bio-financing tight, can service providers find new models? Read More »
Published February 26, 2009
Covance is expanding its biotechnology services facility in Harrogate, UK. The company also received a cGMP Manufacturing License from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK. Read More »
Published November 12, 2008
Merck Serono recently held a cornerstone ceremony at the Merck Serono Biotech Center (MSBC), its production site in Corsiersur-Vevey, Switzerland, to mark the expansion of the site. The expansion will enable the production of greater quantities of Er… Read More »
Published November 7, 2008
InNexus Biotechnology has developed a new antibody product from its DXL platform technology, DXL1218 (EGFR), for the potential treatment of colorectal cancer.     "Recent experimental data suggests that DXL1218 (EGFR) is superi… Read More »
Published October 31, 2008
Sartorius Stedim Biotech GmbH (SSB) signed an agreement to acquire the Swiss-based technology company Wave Biotech AG. The two companies have been working together since 2006 on joint research projects. SSB has been exclusively marketing Wave's pro… Read More »
Published September 12, 2008
MedImmune, the global biologics unit of AstraZeneca, and SBI Biotech Co., Ltd, have entered into a licensing and collaboration agreement to develop and commercialize SBI Biotech's anti-ILT7 protein for the potential treatment of systemic lupus erythe… Read More »
Published May 8, 2008
Enzon Pharmaceuticals, Inc. announced plans to spin off its biotechnology business into an independent company focusing on the development of cancer treatments. Enzon will fund the new company with $150 million, which is expected to provide two to th… Read More »
Published May 6, 2008
Goodwin Biotechnology, Inc. (GBI) has completed the expansion of its cGMP manufacturing space, doubling its capacity. The expansion includes the addition of a 200L and 500L stirred tank bioreactor train to its hollow fiber and perfusion capabilities,… Read More »
Published January 16, 2008
Sartorius Stedim Biotech’s subsidiary, Sartorius Stedim North America, has entered into an exclusive cooperation and supply agreement with Paul Mueller Co. (PMC), covering the U.S., Canada, the U.S. Virgin Islands and Puerto Rico. Sartorius Ste… Read More »


Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On